R., B., M., D., J.L., G., S., L., J., A., J., S., . . . E., N. (2023). Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes.
Chicago Style CitationR., Blanco, et al. Pembrolizumab As First-line Treatment for Advanced NSCLC in Older Adults: A Phase II Clinical Trial Evaluating Geriatric and Quality-of-life Outcomes. 2023.
MLA CitationR., Blanco, et al. Pembrolizumab As First-line Treatment for Advanced NSCLC in Older Adults: A Phase II Clinical Trial Evaluating Geriatric and Quality-of-life Outcomes. 2023.
Warning: These citations may not always be 100% accurate.